

# Edith A Perez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4807392/publications.pdf>

Version: 2024-02-01

49  
papers

4,125  
citations

172457

29  
h-index

214800

47  
g-index

49  
all docs

49  
docs citations

49  
times ranked

5591  
citing authors

#	ARTICLE	IF	CITATIONS
1	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 308-318.	2.4	2
2	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2262.	3.7	9
3	Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study. <i>JMIR Cancer</i> , 2021, 7, e25621.	2.4	2
4	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , 2021, 99, 102229.	7.7	15
5	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.2	112
6	Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. <i>Cancer</i> , 2020, 126, 5239-5246.	4.1	1
7	N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 613-622.	2.5	0
8	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 4.	5.2	49
9	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. <i>Cancer</i> , 2019, 125, 3974-3984.	4.1	67
10	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. <i>BMC Cancer</i> , 2019, 19, 517.	2.6	42
11	Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. <i>Clinical Cancer Research</i> , 2019, 25, 4422-4430.	7.0	6
12	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	1.1	133
13	Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 52.	5.0	12
14	The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes. <i>Clinical and Translational Medicine</i> , 2017, 6, 5.	4.0	48
15	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 141-148.	1.6	327
16	IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. <i>Clinical Cancer Research</i> , 2017, 23, 4203-4211.	7.0	8
17	Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy. <i>Journal of Cardiovascular Development and Disease</i> , 2017, 4, 6.	1.6	5
18	Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors. <i>PLoS ONE</i> , 2016, 11, e0153411.	2.5	30

#	ARTICLE	IF	CITATIONS
19	Breast cancer brain metastases: Molecular subtype, treatment and survival. <i>Breast Disease</i> , 2016, 36, 133-141.	0.8	5
20	Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. <i>Cancer Research</i> , 2016, 76, 3702-3710.	0.9	51
21	N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. <i>Clinical Breast Cancer</i> , 2016, 16, 23-30.	2.4	42
22	Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016, 16, 82-86.	2.4	37
23	Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. <i>Supportive Care in Cancer</i> , 2016, 24, 1219-1226.	2.2	16
24	Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 509-520.	2.5	46
25	“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, 150.	5.0	33
26	Effective Targeting of Estrogen Receptor“Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1306-1316.	4.1	59
27	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. <i>Steroids</i> , 2015, 99, 32-38.	1.8	38
28	Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120“catenin activity. <i>Nature Cell Biology</i> , 2015, 17, 1145-1157.	10.3	93
29	Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2“Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1157-1163.	1.6	342
30	Breast Cancer Management: Opportunities and Barriers to an Individualized Approach. <i>Oncologist</i> , 2011, 16, 20-22.	3.7	43
31	Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 261-271.	2.5	79
32	Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2086-2095.	4.1	428
33	Cardiac Toxicity of ErbB2-Targeted Therapies: What Do We Know?. <i>Clinical Breast Cancer</i> , 2008, 8, S114-S120.	2.4	75
34	Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2008, 83, 679-686.	3.0	175
35	Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1231-1238.	1.6	485
36	Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. <i>Journal of Clinical Oncology</i> , 2007, 25, 3407-3414.	1.6	367

#	ARTICLE	IF	CITATIONS
37	Aromatase inhibitors and bone loss. <i>Oncology</i> , 2006, 20, 1029-39; discussion 1039-40, 1042, 1048.	0.5	30
38	Management Recommendations for Adjuvant Systemic Breast Cancer Therapy. <i>Breast Disease</i> , 2004, 21, 15-21.	0.8	2
39	Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 3700-3704.	1.6	120
40	Gemcitabine and Platinum Combinations in Patients with Breast Cancer Previously Treated with Anthracyclines and/or Taxanes. <i>Clinical Breast Cancer</i> , 2004, 4, S113-S116.	2.4	14
41	Clinical Cardiac Tolerability of Trastuzumab. <i>Journal of Clinical Oncology</i> , 2004, 22, 322-329.	1.6	255
42	Phase I Trial of High-Dose Tamoxifen in Combination with Cisplatin in Patients with Lung Cancer and Other Advanced Malignancies. <i>Cancer Investigation</i> , 2003, 21, 1-6.	1.3	40
43	HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization. <i>Mayo Clinic Proceedings</i> , 2002, 77, 148-154.	3.0	200
44	Weekly Paclitaxel in Women Age 65 and Above with Metastatic Breast Cancer*. <i>Breast Cancer Research and Treatment</i> , 2002, 73, 85-88.	2.5	37
45	Anti-cancer treatment - 12th International Congress. 4-7 February 2002, Paris, France. <i>IDrugs: the Investigational Drugs Journal</i> , 2002, 5, 222-3.	0.7	0
46	The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies. <i>Current Oncology Reports</i> , 2001, 3, 516-522.	4.0	16
47	A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. <i>Cancer</i> , 2000, 88, 124-131.	4.1	85
48	A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. <i>Cancer</i> , 2000, 88, 124-131.	4.1	19
49	Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. <i>Investigational New Drugs</i> , 1998, 16, 69-75.	2.6	25